# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Boston Scientific Corp (NYSE: BSX) to acquire Nalu Medical Inc. for $600 million in cash. Deal expected to close in first half ...
Needham analyst Mike Matson reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $121 price target.
Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target ...
Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:BSX) with a Overweight and raises the price target from $133 ...